semaglutide cardiac protection GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Proposed direct mechanisms of cardiovascular – FLOW Analysis: Semaglutide Delivers Consistent

Major clinical trials demonstrate that these drugs lower major adverse cardiovascular events like myocardial infarction and stroke [8]

Quick Answer: Tirzepatide does not cause high blood pressure and typically reduces both systolic and diastolic blood pressure by 2-8 mmHg through weight loss and improved metabolic function

No Matter Which You Choose, Turn Your GLP-1 Results Into Something You Can Actually Sustain The medication helps control hunger , but it doesn't teach you how to preserve muscle mass or prevent constipation that might require urgent care

A person with a sensitive or overactive immune system might be more likely to report side effects that feel like autoimmune symptoms, even if those reactions are mild or temporary